Literature DB >> 19291782

Red cell exchange transfusion for babesiosis in Rhode Island.

Joshua Spaete1, Eleni Patrozou, Josiah D Rich, Joseph D Sweeney.   

Abstract

We report four cases of clinically severe tick borne babesiosis treated with chemotherapy and adjunctive red cell exchange (RCE) at two Rhode Island hospitals from 2004 to 2007. All RCE procedures were performed using a Cobe Spectra device and were well tolerated without complications. The volume of allogeneic red cells used in the exchange was determined using the algorithm in the apheresis device with the input variables of preprocedure hematocrit, weight, height, an assumed allogeneic red cell hematocrit of 55 and a desired post procedure hematocrit of 27. The preprocedure level of parasitemia varied between 2.4% and 24% and the postprocedure level of parasitemia between 0.4 and 5.5% with an average overall percent reduction in parasitemia of 74%. Retrospectively, application of a new formula to calculate red cell mass appeared to correlate better with the percent reduction in parasitemia. Previous reports of RCE in babesiosis were reviewed. The reported reduction in parasitemia varied from 50% to >90%. Although a preprocedure level of parasitemia of 10% is sometimes used as a threshold for RCE in clinically severe babesiosis, this threshold does not have a firm empirical basis. No postprocedure desired level of parasitemia is indicated nor the mass of allogeneic red cells needed to achieve such a level. We conclude that current estimates of the dose of allogeneic red cells used in RCE are probably inaccurate, advocate a new formula to estimate this dose and suggest that a 90% reduction in parasitemia should be the minimally desired target of RCE in babesiosis.

Entities:  

Mesh:

Year:  2009        PMID: 19291782     DOI: 10.1002/jca.20197

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  15 in total

1.  Tick-borne disease (babesiosis).

Authors:  Hanish Jain; Garima Singh; Rahul Mahapatra
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-08-24

2.  Severe Babesia microti infection presenting as multiorgan failure in an immunocompetent host.

Authors:  Juan G Ripoll; Mahrukh S Rizvi; Rebecca L King; Craig E Daniels
Journal:  BMJ Case Rep       Date:  2018-05-30

Review 3.  Babesiosis.

Authors:  Edouard G Vannier; Maria A Diuk-Wasser; Choukri Ben Mamoun; Peter J Krause
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

Review 4.  Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review.

Authors:  Edgar Sanchez; Edouard Vannier; Gary P Wormser; Linden T Hu
Journal:  JAMA       Date:  2016-04-26       Impact factor: 56.272

5.  "Human babesiosis": an emerging transfusion dilemma.

Authors:  Helieh S Oz; Karin H Westlund
Journal:  Int J Hepatol       Date:  2012-03-28

6.  Diagnosis and management of human babesiosis.

Authors:  Subhash Chandra Parija; Dinoop Kp; Hrudya Venugopal
Journal:  Trop Parasitol       Date:  2015 Jul-Dec

7.  Babesiosis Occurrence among the Elderly in the United States, as Recorded in Large Medicare Databases during 2006-2013.

Authors:  Mikhail Menis; Richard A Forshee; Sanjai Kumar; Stephen McKean; Rob Warnock; Hector S Izurieta; Rahul Gondalia; Chris Johnson; Paul D Mintz; Mark O Walderhaug; Christopher M Worrall; Jeffrey A Kelman; Steven A Anderson
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

8.  Exchange transfusion for babesiosis when, how, and how long?

Authors:  Pramod K Guru; John C O Horo; Heidi D Lehrke; Jeffrey L Winters; John W Wilson
Journal:  Indian J Crit Care Med       Date:  2016-11

9.  Rise in Babesiosis Cases, Pennsylvania, USA, 2005-2018.

Authors:  David Ingram; Tonya Crook
Journal:  Emerg Infect Dis       Date:  2020-08       Impact factor: 6.883

10.  Parasite burden and red blood cell exchange transfusion for babesiosis.

Authors:  Jane O'Bryan; Amit Gokhale; Jeanne E Hendrickson; Peter J Krause
Journal:  J Clin Apher       Date:  2020-11-12       Impact factor: 2.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.